Write in a clean editor, then format for Frontiers in Molecular Medicine in one click — DocuGuru applies the official Frontiers template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Frontiers in Molecular Medicine is a peer-reviewed journal published by Frontiers, covering CAR-T cell therapy research, Neuroinflammation and Neurodegeneration Mechanisms, Computational Drug Discovery Methods. Over its lifetime it has published 95 papers, which have received 727 citations.
| Publisher | Frontiers |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Frontiers in Molecular Medicine, 12(3), pp. 45–58.
Formats any DOI in Frontiers in Molecular Medicine style. No sign-up. |
| Publishes research in | CAR-T cell therapy research Neuroinflammation and Neurodegeneration Mechanisms Computational Drug Discovery Methods Mitochondrial Function and Pathology CRISPR and Genetic Engineering |
| ISSN | 2674-0095 |
| Citation impact (2-yr) | 3 |
| h-index | 15 |
| i10-index | 28 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | University of Eastern Finland |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The heart has been the center of numerous transcriptomic studies in the past decade. Even though our knowledge of the key organ in our cardiovascular system has significantly increased over the last years, it is still not fully understood yet. In recent years, extensive efforts were made to understand the genetic and transcriptomic contribution to…
This paper discusses the challenges of producing CAR-T cells for cancer treatment and the potential for Artificial Intelligence (AI) for its improvement. CAR-T cell therapy was approved in 2018 as the first Advanced Therapy Medicinal Product (ATMP) for treating acute leukemia and lymphoma. ATMPs are cell- and gene-based therapies that show great promise for treating…
The use of cancer immunotherapies is not novel but has been used over the decades in the clinic. Only recently have we found the true potential of stimulating an anti-tumor response after the breakthrough of checkpoint inhibitors. Cancer immunotherapies have become the first line treatment for many malignancies at various stages. Nevertheless, the clinical results…
Indole and p-cresol are precursors of the most important uremic toxins, generated from the fermentation of amino acids tryptophan and tyrosine by the proteolytic community of intestinal bacteria. The present study focused on the relationship between the microbiome composition, the fecal levels of indole and p-cresol, and their kinetics of generation/degradation in fecal cultures. The…
Background: T cells that are genetically modified with chimeric antigen receptor (CAR) hold promise for immunotherapy of cancer. Currently, there are intense efforts to improve the safety and efficacy of CAR T cell therapies against liquid and solid tumors. Earlier we designed a novel CAR backbone (FiCAR) where the spacer is derived from immunoglobulin (Ig)…
